Skip to main content

Table 4 Hazard ratios for disease-free survival and the combined risk scores of serum lipocalin-2 and MMP-9 levels according to BMI and lymph node status

From: The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer

  Combined score a No. of total patients ( N =303) No. of events ( N =87) Adjusted HRb(95% CI) P P interaction
BMI < 25 t1 81 17 1.00 (reference)   0.031
N=229 t2 77 20 1.74 (0.88-3.42) 0.110  
  t3 71 25 3.17 (1.66-6.06) <.0001  
  P trend    1.78 (1.29-2.46) <.0001  
BMI ≥ 25 t1 20 13 1.00 (reference)   
N =74 t2 23 15 0.92 (0.27-3.08) 0.886  
  t3 31 21 0.92 (0.32-2.63) 0.881  
  P trend    0.96 (0.57-1.62) 0.891  
LN – t1 57 9 1.00 (reference)   0.094
N =170 t2 55 12 3.28 (1.19-9.07) 0.022  
  t3 58 19 5.36 (2.18-13.2) <.0001  
  P trend    2.21 (1.45-3.35) <.0001  
LN + low 44 29 1.00 (reference)   
N =133 medium 45 29 1.31 (0.64-2.68) 0.462  
  high 44 28 1.43 (0.69-2.95) 0.335  
  P trend    1.20 (0.84-1.71) 0.328  
  1. a The subjects were categorized into three groups based on the tertiles of combined score: low (1.092-3.463), medium (3.464-4.997) and high (4.998-14.276) score groups.
  2. b Adjusted for BMI (< 25 and ≥ 25 kg/m2), TNM stage (I, II, and III), ER status (positive and negative) and radiation therapy (Yes and No). For stratified analysis by BMI group, the stratification variable of interest (BMI) was not included as covariate in the model.
  3. LN –, lymph-node negative; LN +, lymph-node positive.